Valerio Therapeutics

ALVIO

Company Profile

  • Business description

    Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

  • Contact

    49 Boulevard du General
    Martial Valin
    Paris75015
    FRA

    T: +33 145587600

    https://www.valeriotx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    38

Stocks News & Analysis

stocks

Australian stocks will crush housing over the next decade, one year on

James Gruber looks back on his forecast for Australian equities and the housing market 
stocks

10 best US blue-chip stocks to buy for the long term

The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks

What next for Tesla as 2024 deliveries disappoint?

Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,599.4056.500.66%
CAC 407,401.8887.47-1.17%
DAX 4020,261.8478.73-0.39%
Dow JONES (US)42,345.12183.24-0.43%
FTSE 1008,224.7020.58-0.25%
HKSE19,279.84167.74-0.86%
NASDAQ19,443.9645.72-0.23%
Nikkei 22539,981.06102.24-0.26%
NZX 50 Index13,043.111.050.01%
S&P 5005,891.4517.58-0.30%
S&P/ASX 2008,349.1064.000.77%
SSE Composite Index3,230.170.520.02%

Market Movers